Esophageal Cancer Drugs Market - Regional Insights
On the basis of region, the global esophageal cancer drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global esophageal cancer drugs market during the forecast period, owing to high prevalence of esophageal cancer in this region. For instance, the according to American Cancer Society’s report, it projected that around 17,650 new esophageal cancer cases will be diagnosed (13,750 in men and 3,900 in women) in the U.S. by 2019.
Asia Pacific is expected to witness rapid growth in the esophageal cancer drugs market during the forecast period, owing to rise in clinical trials conducted in Asian countries for novel drugs to treat esophageal cancer. For instance, National Cancer Center Hospital, Tokyo started a clinical trial in December 2018, which evaluated the comparative study between combination therapy with induction DCF (docetaxel plus cisplatin and 5-fluorouracil) versus definitive chemo-radiotherapy for locally advanced carcinoma of the thoracic esophagus.
Esophageal Cancer Drugs Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients